Parents' willingness to pay for diminishing children's pain during blood sampling

Jean-Blaise Wasserfallen1, Christine Currat-Zweifel, Jean-Jacques Cheseaux

  • 1Institute of Health Economics and Management, University Hospital CHUV, Lausanne, Switzerland. jwasserf@chuv.hospvd.ch

Paediatric Anaesthesia
|January 18, 2006
PubMed

Insights

Parents are willing to pay for local anesthetics to reduce children's stress during blood sampling. Median willingness to pay (WTP) for pain management drugs aligns with actual costs, suggesting potential for insurance coverage.

Area of Science:

  • Pediatric Medicine
  • Pain Management
  • Health Economics

Background:

  • Blood sampling is a common yet stressful procedure for children.
  • Developed local anesthetics are costly and lack insurance reimbursement.
  • Assessing parental willingness to pay (WTP) for these drugs is crucial.

Purpose of the Study:

  • To evaluate parents' willingness to pay (WTP) for local anesthetic drugs to alleviate procedural pain in children.
  • To determine parental WTP across different scenarios: avoiding blood sampling (ABS), prescription use (PD), and over-the-counter (OTC) purchase.

Main Methods:

  • A 6-month study involving parents of children undergoing blood sampling during general (GV) or specialized visits (SV).
  • WTP was assessed using a payment card system with randomized ascending/descending price orders (AO/DO) across three scenarios.
  • Fifty-six responses were collected, yielding a 40% response rate.

Main Results:

  • Median WTP was 40 (ABS), 25 (PD), and 10 (OTC), approximating the drug's actual price.
  • WTP as a percentage of monthly income was 0.71% (ABS), 0.67% (PD), and 0.20% (OTC), with a maximum of 10%.
  • Results were consistent between general and specialized visits.

Conclusions:

  • Parental WTP for pediatric pain management during blood draws is significant, though assessment in outpatient settings presents challenges.
  • The median WTP closely matches the drug's real-world price.
  • Findings support advocating for insurance coverage for these pain-reducing medications.
Abstract